整合素、黏附分子、部分趋化因子及其他分子在炎症性肠病中的作用及研究进展

The Role and Research Progress of Integrins, Adhesion Molecules, Partial Chemokines and Other Molecules in Inflammatory Bowel Disease

摘要: 随着炎症性肠病(IBD)治疗药物的不断更新，其治疗药物由传统氨基水杨酸、糖皮质激素和免疫抑制剂拓展至靶向生物制剂及小分子合成药物。但其出现的各种不良并发症以及药物失应答与安全性等问题不可避免，而作为参与淋巴细胞归巢过程中的整合素、黏附分子、部分趋化因子及其他分子，可能是未来靶向治疗IBD甚至自身免疫性疾病的重要方向。本文通过综述靶向参与淋巴细胞归巢的整合素、黏附分子和趋化因子与其他分子，简述了其在控制IBD疾病中的研究进展，为开发新型生物制剂治疗IBD提供更广阔的临床前景。

Abstract: With the continuous development of inflammatory bowel disease (IBD) treatment drugs, its therapeutic drugs have expanded from traditional aminosalicylic acid, glucocorticoids and immunosuppressants to targeted biologics and small molecule synthetic drugs. However, various adverse complications and drug failure and safety problems are inevitable. Integrins, adhesion molecules, partial chemokines and other molecules involved in the homing process of lymphocytes may be an important direction for targeted therapy of IBD and even autoimmune diseases in the future. This article reviews the integrins, adhesion molecules, chemokines and other molecules involved in lymphocyte homing, and briefly reviews their research progress in the control of IBD diseases, providing a broader clinical prospect for the development of new biologics for the treatment of IBD.